Concord Medical Services Holdings Limited — FY2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023; filed April 19, 2024. This is an annual report, not a standalone fourth-quarter filing. The company reports in RMB; U.S. dollar figures are approximate translations.
Business context
Concord Medical is a Cayman Islands holding company whose operations are principally conducted through PRC subsidiaries. It provides oncology care through self-owned hospitals and clinics and supplies equipment, leasing, management, technical support and related services through its network business. At year-end it operated six self-owned cancer hospitals, clinics and imaging centers, an internet hospital, and 10 cooperative centers.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | RMB537.4 million (US$75.7 million) | RMB472.1 million |
| Gross loss / margin | RMB76.6 million / (14.3%) | RMB152.4 million / (32.3%) |
| Operating loss | RMB463.0 million | RMB525.0 million |
| Net loss | RMB531.0 million (US$74.8 million) | RMB769.0 million |
| Net loss attributable to parent | RMB297.7 million | RMB489.7 million |
| Net cash used in operating activities | RMB276.5 million (US$38.9 million) | RMB216.7 million |
| Cash and cash equivalents at year-end | RMB58.1 million; restricted cash was RMB32.3 million | RMB158.3 million; restricted cash was RMB1.1 million |
| Bank and other borrowings | RMB3,036.2 million, including RMB1,042.2 million current | RMB2,984.0 million, including RMB512.6 million current |
| Net current liabilities | RMB1,334.2 million | Not clearly stated in the supplied filing text |
FY2023 basic and diluted loss per ordinary share was RMB2.27 (approximately US$0.32). Total shareholders’ deficit attributable to Concord Medical was RMB2,121.9 million; consolidated total equity was RMB1,747.0 million.
Material changes versus FY2022
- Revenue rose 13.8%, as hospital-business revenue increased 46.6% to RMB319.1 million, reflecting Guangzhou Hospital’s ramp-up and recovery at Shanghai facilities after COVID-related disruption in 2022.
- Network-business revenue declined 14.2% to RMB218.3 million, principally because management and technical support agreements expired and software-development activity was lower. Network gross profit fell to RMB11.8 million from RMB29.2 million.
- Gross loss narrowed to RMB76.6 million from RMB152.4 million, but the company remained loss-making at the gross-profit level. Operating loss also narrowed, while interest expense increased to RMB165.7 million from RMB120.4 million.
- Net loss improved from RMB769.0 million to RMB531.0 million. FY2022 included RMB216.6 million of other expenses, mainly related to termination of the Beijing Proton Medical Center cooperation agreements, and a RMB61.5 million loss on disposal of subsidiaries. FY2023 included a RMB37.5 million gain on sale of part of an equity-method investment and RMB10.8 million of other expenses.
- Operating cash outflow increased by RMB59.8 million year over year. Cash and cash equivalents fell by RMB100.1 million, while current borrowings increased.
Outlook, risks and unusual items
- Liquidity and going concern: The filing describes recurring losses, negative operating cash flow, RMB1,334.2 million of net current liabilities and RMB4,064.6 million of accumulated deficit. Management says substantial doubt about continuing as a going concern has been alleviated by financing plans and subsequent funding. However, the auditor’s report still highlights substantial doubt and states that its unmodified opinion is not modified with respect to that matter.
- Subsequent funding: Concord Healthcare listed shares in Hong Kong on January 9, 2024. The filing reports gross proceeds of HK$562.9 million and receipt of HK$554.9 million (approximately US$71.0 million) by the report date. The group also received RMB90.0 million under five loan contracts entered into from January through March 2024. These proceeds and loans are important to the liquidity assessment, but do not remove execution and repayment risks.
- Debt and collateral: Borrowings carry material interest costs; weighted-average rates at year-end were 8.19% for short-term and 7.42% for long-term borrowings. The company pledged equipment, receivables, land-use rights, construction in progress and investments. Debt covenants, refinancing needs and scheduled repayments could constrain operations.
- Capital plans: Management estimated 2024 capital expenditures of approximately RMB131 million, mainly for Shanghai and Guangzhou hospital construction and equipment. Shanghai Hospital is expected to begin operations in January 2026, with its proton center planned for 2027; Guangzhou’s proton center still faced a delayed procurement-license approval at the report date. An NHC plan adjustment announced in February 2024 added eight proton/heavy-ion systems for privately run institutions, which management said could improve approval prospects.
- Controls and reporting: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2023. The identified material weakness was insufficient accounting staff and resources with appropriate U.S. GAAP and SEC-reporting expertise. Management described training and third-party assistance as remediation measures; the auditor did not attest to internal-control effectiveness.
- Other key risks: PRC regulatory, licensing and data-privacy uncertainty; dependence on public medical-insurance reimbursement and hospital partners; concentration in Shanghai and Guangzhou, which generated 57.4% of revenue from the company’s hospitals and clinics in 2023; reliance on a limited supplier base; and potential NYSE delisting risk if PCAOB inspection access again becomes unavailable for the required period. The company also disclosed that its internet hospital did not hold an ICP license.
- Governance and distributions: The company paid no dividends in 2021–2023 and has no near-term dividend plan. Its dual-class structure gives Class B shares ten votes each; CEO Jianyu Yang was reported to control 73.2% of voting power.
Most important facts for investors to verify
- Reconcile the going-concern disclosure: auditor’s substantial-doubt language versus management’s conclusion that subsequent Hong Kong listing proceeds and new loans alleviate the doubt; verify available cash, restrictions and debt maturities.
- Track collections and credit quality: FY2023 included a sharp rise in doubtful-account provisions, and the company reported RMB59.0 million of network-business receivables and RMB30.5 million of total receivable allowances.
- Confirm the timing, cost and funding of Shanghai Hospital and both proton-center plans, including required procurement and operating approvals.
- Assess whether hospital revenue growth can translate into positive gross profit and operating cash flow, given continued negative margins and the network business’s lower revenue and profit.
- Monitor remediation of the material weakness, refinancing and covenant compliance, supplier concentration, and evolving PRC regulatory and PCAOB inspection requirements.